Structure Therapeutics Statistics
Share Statistics
Structure Therapeutics has 61.84M shares outstanding. The number of shares has increased by 24.61% in one year.
| Shares Outstanding | 61.84M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -3.31% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 54.18M |
| Failed to Deliver (FTD) Shares | 121 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 10.44M, so 18.24% of the outstanding shares have been sold short.
| Short Interest | 10.44M |
| Short % of Shares Out | 18.24% |
| Short % of Float | 19.28% |
| Short Ratio (days to cover) | 15.69 |
Valuation Ratios
The PE ratio is -16.71 and the forward PE ratio is -48.01.
| PE Ratio | -16.71 |
| Forward PE | -48.01 |
| PS Ratio | 0 |
| Forward PS | 34.7 |
| PB Ratio | 3.31 |
| P/FCF Ratio | -18.34 |
| PEG Ratio | n/a |
Enterprise Valuation
Structure Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 19.14, with a Debt / Equity ratio of 0.
| Current Ratio | 19.14 |
| Quick Ratio | 19.14 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.32 |
| Cash Flow / Debt | -55.2 |
| Interest Coverage | -7.67 |
Financial Efficiency
Return on equity (ROE) is -0.2% and return on capital (ROIC) is -22.48%.
| Return on Equity (ROE) | -0.2% |
| Return on Assets (ROA) | -0.19% |
| Return on Capital (ROIC) | -22.48% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -658.97K |
| Employee Count | 136 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 236.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -47.28% in the last 52 weeks. The beta is -5.13, so Structure Therapeutics 's price volatility has been lower than the market average.
| Beta | -5.13 |
| 52-Week Price Change | -47.28% |
| 50-Day Moving Average | 36.51 |
| 200-Day Moving Average | 38.98 |
| Relative Strength Index (RSI) | 39.31 |
| Average Volume (20 Days) | 779.99K |
Income Statement
In the last 12 months, Structure Therapeutics had revenue of $0 and earned -$89.62M in profits. Earnings per share was $-2.44.
| Revenue | 0 |
| Gross Profit | -949.17K |
| Operating Income | -102.78M |
| Net Income | -89.62M |
| EBITDA | -102.78M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.44 |
Balance Sheet
The company has $129.79M in cash and $5.45M in debt, giving a net cash position of $124.34M.
| Cash & Cash Equivalents | 129.79M |
| Total Debt | 5.45M |
| Net Cash | 124.34M |
| Retained Earnings | -206.57M |
| Total Assets | 933.22M |
| Working Capital | 890.22M |
Cash Flow
In the last 12 months, operating cash flow was -$79.49M and capital expenditures -$2.17M, giving a free cash flow of -$81.66M.
| Operating Cash Flow | -79.49M |
| Capital Expenditures | -2.17M |
| Free Cash Flow | -81.66M |
| FCF Per Share | -2.22 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
GPCR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -7.82% |
| FCF Yield | -4.23% |
Analyst Forecast
The average price target for GPCR is $83, which is 166.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $83 |
| Price Target Difference | 166.1% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 30.12 |
| Piotroski F-Score | 3 |